Wellington Management Group
VRTX icon

Wellington Management Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Wellington Management Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-100
Closed -$280K – 2304
2017
Q1 		$280K Buy
+100
New +$8.8K ﹤0.01% 2164

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wellington Management Group's VRTX Position: Q1 2026 in Review

Wellington Management Group reduced its Vertex Pharmaceuticals (VRTX) stake by 16% in Q1 2026, selling an estimated $284M and leaving 3,212,589 shares worth $1.43B. The position accounts for 0.27% of the portfolio, ranked #84.

Wellington Management Group first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.66B in Q2 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Wellington Management Group held 3,212,589 shares of Vertex Pharmaceuticals worth $1.43B as of Q1 2026.
  • Wellington Management Group sold 609,142 Vertex Pharmaceuticals shares in Q1 2026, an estimated $284M.
  • Vertex Pharmaceuticals made up 0.27% of Wellington Management Group's portfolio in Q1 2026, its #84 holding.
  • Wellington Management Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Wellington Management Group's Vertex Pharmaceuticals position peaked at $2.66B in Q2 2023.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.